Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood.
Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
High diagnostic accuracy :
Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI.
Convenience :
No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling
Efficiency:
Provides diagnosis opportunities to more people in situations where personnel and devices are limited
MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm. An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy and reproducibility among these combinations. DEVELOPMENT PROCESS: - MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University. - After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy. - After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
Application Suspected case test in epidemic area Early test of fever clinic and CDC Screening of primary medical institutions Inspection of floating population in public areas Performance Characterisitics Sample tyep: nasal swab Time to result: 15-20 minutes Sensitivity: 97.70% Specificity: 99.84% Accuracy:98.97% Layperson study statistics 99.84% of non-professionals carried out the test without requiring assistance 99.82% of different types of results were interpreted correctly. Parameters: A Short Test Time: 15 mintues B Accuracy: More than 98.1% C Sensitivity: 96.4% Specificity: 100% D Easy operation: Nasal Swab E One Step solution F Lower cost with high efficiency G Package: 1 Test/Kit, 5 Tests/Kit, 25 Tests/Kit H It can detection for Omicron Virus Price and Minumum Quantity Price FOB in USD: 1.5Minimum Order Qty: 500000 Pieces Production Capacity: 100 Million Boxes Per WeekPackaging: 1,5,20,25,40,100,200 Pcs Per Box Sample: Available. Sample Cost Born By Buyer Product Model And Origin Brand: jwfModel: jwf01 Seller Code: Jwf Standards: Ce Competitive Advantages Lower cost with high efficiency Detection for omicron virus Easy operation Short test time Other Details Omicron covid test kit Covid test kit Omicron test card Covid test card
PANCCHECK is a blood test solution that enables early diagnosis of pancreatic cancer with 94% accuracy is under development. PANCCHECK DEVELOPMENT PROCESS: While effective early diagnostic methods for pancreatic cancer are currently lacking, BERTIS is developing a technology that enables early diagnosis of pancreatic cancer with a small blood sample. Through research, we have identified 10 protein biomarkers as a diagnostic marker panel for pancreatic cancer. Following algorithm development and validation, we have uncovered a combination of markers that demonstrates a high accuracy of 98% and is applicable in clinical settings.
Cancer Diagnostic Device
It is a breakthrough and powerful diagnostic system for use by doctors and hospitals. It offers early and multiple disease detection capabilities, reducing diagnoses procedures to a minimum. Due to the complexity of our body systems, diagnosing internal disorders can be difficult. So physicians often refer patients for a series of further tests before drawing final conclusions. Medex testÖ is presently in use in: Primary and outpatient care / services Emergency wards Cardiology Oncology Hospital departments of internal medicine Gastroenterology DoctorÆs practices Occupational and medical insurance groups What is Medex testÖ? The governing principle behind this new technology is based on information from special zones on the body called dvzÆs (dermatome- visceral zones). Measurements taken from the hands and feet are expressions of the skinÆs electrical conductivity and resistance, and reflect changes in normal organ function. It is principally designed to detect early cancers and tumors of the colon, liver, stomach and most other organs. 6kg
We are the authorized distributing partner of the South Korean diagnostic manufacturer BioTNS. Our role is to distribute in South Korea and overseas the Covid-19 RT-PCR PNA kits. 1 kit allows you to test 100 patients. - CE approved - US FDA approved Contact us to receive your quotation.
One Step Fecal Occult Blood (FOB) Rapid Test Cassette (Feces) Cat. No.: RH0301T INTENDED USE The One-Step Fecal Occult Blood (FOB) Diagnostic Kit is a qualitative detection of human occult blood in feces forself-testing. PRINCIPLE The One-Step Fecal Occult Blood (FOB) Diagnostic Kit is an immunochromatographic sandwich method, which employ two specific monoclonal antibodies to selectively identify hemoglobin in test samples. The result is very specific, and easier to interpret than those of guaiac-based test. The sensitivity is very high with the ability to detect 200ng/ml hemoglobin in feces. In addition, the accuracy of the test is not affected by interfering substances, and dietary restriction is not necessary. STORAGE The kits should be stored at temperature 4-30�°C, the sealed pouch for the duration of the shelf life (24 months). Do the test in 1 hour after open the pouch. WARNING AND PRECAUTIONS 1. For in vitro diagnostic use only. 2. Do not use kit beyond the expiration date. 3. Patient specimens may contain infectious agents and should be handled as though capable of transmitting disease. Wear disposable gloves throughout the specimen collection and assay procedures. 4. The test device should not be reused. REAGENTS AND MATERIALS PROVIDED 1. One pouched cassette with desiccant. 2. One operating Instruction MATERIALS REQUIRED BUT NOT PROVIDED 1. Clock or Timer SPECIMEN COLLECTION AND PREPARATION 1. Collect stool sample by using the sample collection device provided. 2. Unscrew the top of the sample collection device, take out the sample collection stick, and collect the sample by dipping the stick into 3 different places of the stool sample. 3. Put the sample collection stick back in the sample collection device and screw together tightly. 4. If the sample cannot be tested on the day of collection, store the stool sample at 4C. Bring the specimen to room temperature before testing. ASSAY PROCEDURE 1. Remove the test device from foil pouch by tearing along the notch. 2. Specimen collection. Please see also SAMPLE COLLECTION AND PREPARATION 3. Shake the sample collection device several times. 4. Holding the sample collection device upright, carefully unscrew the tip of collection device. 5. Squeeze 2-3 drops of the sample solution on the test sample pad. 6. Read the test results in 5 minutes. INTERPRETATION OF RESULTS Negative: Only one colored band appears on the control region (C). No colored band in the test region (T). Positive: In addition to the control band (C), a distinct colored band also appears in the test region (T). Invalid: If no bands appear, or a test band appears without a control band, the test should be repeated using a new test device.
Supplier: Early diagnostic device
Companion Diagnostics (CDx) provide a companion diagnostic solution through pathway analysis based on RNA and protein quantification information respective to subtypes from each diseases. For precision medicines developed based on multi-omics analysis, biomarkers can be used to identify target patients in advance. Global pharmaceutical companies are active in the use of companion diagnostics as a key strategic tool in clinical development programs. PASS provides solutions for the entire process from discovery of drug candidates to non-clinical to clinical trials through pan-omics technology. Bertis has array of innovative and reliable technology to increase the safety and efficacy of an investigational drug across the clinical research landscape, including solutions for the discovery of biomarkers for companion diagnostics and the determination of clinical targets through functional analysis.
